Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality
Arbel R, Hammerman A, Azuri J
Am J Cardiol. Pub. online June 22, 2018
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Cardiovascular and Renal Outcomes with Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
Neuen BL, Ohkuma T, Neal B, et al.
Circulation. Pub. online June 25, 2018.
Leggi
Trends in Weight Loss Efforts Among US Adolescents with Overweight and Obesity
Hawkins DR, Kazmierski K, Hansen A, et al.
JAMA Pediatr. Pub. online June 25, 2018
Leggi
Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care
Bally L, Thabit H, Hartnell S, et al.
N Engl J Med. Pub. online June 25, 2018
Leggi
Glycemic Control in Nonpregnant Adults With Type 2 Diabetes
Tung EL, Davis AM, Laiteerapong N
JAMA. 2018;319(23):2430-31
Leggi
Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone
Young LH, Viscoli CM, Schwartz GG, et al.
Circulation. Pub. online June 22, 2018.
Leggi
Agonism of receptors in the gut–pancreas axis in type 2 diabetes: are two better than one?
Rayner CK, Horowitz M
The Lancet. Pub. online 22 June 2018.
Leggi
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Ambery P, Parker VE, Stumvoll M, et al.
The Lancet. Pub. online 22 June 2018.
Leggi
Lessons learned from lifestyle prevention trials in gestational diabetes mellitus
Egan AM, Simmons D
Diabetic Medicine. Pub. online 25 June 2018.
Leggi
Improving outcomes in gestational diabetes: does gestational weight gain matter?
Aiken CEM, Hone L, Murphy HR, et al.
Diabetic Medicine. Pub. online 22 June 2018.
Leggi